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1. Introduction 
In 1988 the US Surgeon General’s report stated that tobacco use, in any form, is addicting as 
a result of its nicotine content and defined the processes determining tobacco addiction as 
“similar to those that determine addiction to drugs such as heroin and cocaine” (U.S. Surgeon 
General, 1988). Tobacco smoking has been classified by the WHO International 
Classification of Diseases (ICD-10) under the "Mental and behavioural disorders” (F00-F99 
(http://apps.who.int/classifications/apps/icd/icd10online/). Continuous use of nicotine 
induces adaptive changes in the CNS leading to tolerance, physical or physiological 
dependence, sensitization, craving, reward and relapse. Drug addiction has been defined by 
Koob (2008) as "a chronically relapsing disorder characterized by compulsive drug use and loss of 
control over drug intake". Indeed Koob (2008) proposed that addiction includes three different 
stages, which are: "preoccupation/anticipation, binge/intoxication, and withdrawal/negative affect". 
As a final result chronic use of nicotine produces ‘tolerance’, an occurrence that reduces the 
effect of a drug given dose (Fig. 1.). 
 
Fig. 1. Steps signals involved in the circuit of nicotine addiction (adapted from Russo, 2011). 
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Cessation of tobacco use determines a withdrawal syndrome, characterized by agitation, 
irritation, frustration or anger, concentration difficulty, depressed mood, anxiety, 
restlessness, decreased heart rate and increased appetite or weight gain (Benowitz, 2010; 
Perkins, 2002; Shiffman et al., 2004). These symptoms occur after four to twelve hours, peak 
after one week and decrease progressively over time (Perkins, 2002). Nicotine addiction is 
sustained by the individual positive effects experienced during smoking, and by the wish to 
hold off the negative symptoms of nicotine withdrawal. Thus, episodic and repetitive doses 
of nicotine are indispensable to maintain normal levels of functioning. Moreover, stress 
conditions, processes concerning consciousness, evaluation and response to negative, 
threatening or, challenging events or stimuli have been found to exacerbate nicotine 
withdrawal symptoms and increase vulnerability to relapse (Morissette et al., 2007).  
2. Neurochemistry of Nicotinic receptor (nAChR) 
The functional properties of nicotine are related to its interaction with the nicotine receptors 
(nAChR). nAChR are acetylcholine gated ion channels consisting of homo- or hetero-
pentamers subunits arranged symmetrically around a membrane perpendicular axis, 
outlining the ionic hole (Russo et al., 2006; Taly et al., 2009) (Fig. 2.). 
 
Fig. 2. Nicotinic Receptors. nAChR consist of homo- (e.g. or a9, non the left) or hetero-
pentamer (e.g. composed of the various subunits 
) that are arranged symmetrically around an axis perpendicular to the 
membrane, thus delineating the ionic pore. The ┙ subunits are distinguished by the presence 
of adjacent (vicinal) Cysteine residues in loop C, and this originally defined ┙ subunits as 
agonist-binding subunits. The homomeric ┙7 nAChR is a special case, since having five 
agonist-binding sites per receptor can bind from two to five molecules of agonist. 7-nAChR 
utilizes multiple calcium amplification pathways to efficiently raise the intracellular calcium 
levels by subsequent activation of voltage-gated calcium channels as well as calcium release 
from the endoplasmic reticulum (Russo et al., 2006; Taly et al., 2009).  
The composition and stoichiometry of the pentamer determines receptor pharmacology, 
cations selectivity, desensitization kinetics and spatial distribution. Receptors containing ┙4 
and ┚2 subunits are the most abundant in the CNS accounting for the majority of nicotine 
high affinity binding sites (Flores et al., 1992; Schoepfer et al., 1988). It has been shown, by  
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pharmacological and ligand-binding experiments, that nAChR containing the ┚2-subunit 
(┚2*nAChR, the asterisk indicates the possibility of other subunits to be incorporated in the 
receptors) bind to nicotine with high affinity (Changeux et al., 1998). -containing nAChR, 
which have been implicated in nicotine self-administration (Picciotto et al., 1998), do not 
influence the onset of nicotine withdrawal symptoms (Salas et al., 2004). Evidence shows 
that acute nicotine self-administration is absent if the * receptors are deleted (Marubio et 
al., 2003; Pons et al., 2008). Activation of  nAChR is sufficient to sustain nicotine-induced 
reward, tolerance and sensitization (Tapper et al., 2004). Since the  and  subunits are 
coexpressed within in the medial habenula (MHb), in the interpeduncular nucleus (IPN) 
and in the peripheral ganglia, it is likely that  and nAChR may be involved in the 
mechanisms of nicotine withdrawal. It has been shown that * nAChR expressed in the 
VTA (ventral tegmental area) are necessary for the effects of systemic nicotine on DA 
(dopamine) neuron activity and DA-dependent behaviours, such as locomotion and 
reinforcement. It was proposed that both  and  receptors are necessary for (at least 
some of) the effects of nicotine on the DA system. In the brain, the homomeric  subtype is 
the most abundant and widespread nAChR (Breese et al., 1997; Quik et al., 2000), being 
involved in the modulation of glutamatergic and cholinergic neurotransmitter release, in the 
synaptic plasticity, in the regulation of neuronal growth, in the differentiation and survival, 
in the regulation of calcium-dependent gene expression and in the mediation of circuit 
excitability (reviewed in Gotti & Clementi, 2004). New data support a model in which the ┙7 
nAChR, found on glutamate terminals, increases glutamate release contributing to 
presynaptic facilitation and synaptic plasticity and enhancing dopamine release from 
neighbouring boutons (Livingstone et al., 2010). The regulation of the nAChR is linked to 
their intrinsic property of being allosteric receptors. (Changeux & Edelstein, 2005). Thus 
nAChR are susceptible to desensitization and inactivation following, or in some cases 
independent of, channel opening (Giniatullin et al., 2005). Desensitization represents a 
decrease or loss of biological response after prolonged or repetitive stimulation by an 
agonist, such as nicotine, or a neurotransmitter. Indeed, when nicotine is continuously 
applied, nAChR become ‘desensitized’ (i.e. temporarily inactive) (Katz & Thesleff, 1957; 
Quick & Lester, 2002). The sensitisation-desensitization is correlated to the property of 
nAChR to increase their expression (upregulation) when exposed to nicotine (Vallejo et al., 
2005; Gahring et al., 2010). Subtypes containing  and  are not up-regulated by 
chronic nicotine administration (Mao et al., 2008; Marks et al., 1992 ), whereas - or 
containing nAChR (Tapper et al., 2004; Nashmi et al., 2007), containing subunits are up-
regulated following repeated nicotine administration (McCallum et al., 2006). ┙7 
upregulation occurs at higher nicotine concentrations than are required to increase ┙4┚2 
nAChR (Pauly et al., 1991; Rasmussen & Perry, 2006; Kawai & Berg, 2001). Up-regulation of 
-containing receptors, after nicotine administration, is a process which less clear, since 
studies report either upregulation (Parker et al. 2004), down-regulation (Lai et al., 2005; 
Perry et al., 2007) or no change (Drenan et al., 2008; McCallum et al., 2006).  
3. Mechanism of nicotine addiction 
Although the molecular mechanisms leading to and maintaining NA are not completely 
understood, they involve the regulation of brain monoamines levels and in particular DA 
(Benowitz, 2010; Changeux, 2009). Nicotine stimulates those nAChR placed principally in 
the ventral tegmental area, in the nucleus accumbens and in the pedunculopontine and  
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laterodorsal tegmental nuclei, important neuronal structures of the mesolimbic reward 
pathway (Brunzell et al., 2009; Dani, 2003; Exley & Cragg, 2008; Sharma & Brody, 2009; 
Schiltzet al., 2005). It has been proposed that the change from voluntary drug use to a more 
habitual and compulsive drug use, corresponds to a transition, at the neural level, from 
prefrontal cortical to striatal control, as well a progression from ventral to more dorsal 
domains of the striatum, involving its dopaminergic innervation (Everitt & Robbins, 2005). 
These neural transitions may themselves depend on the neuroplasticity in both cortical and 
striatal structures that is induced by chronic self-administration of drugs. Several nAChR 
subtypes such as: ┙4┙6┚2┚3, ┙4┚2, ┙4┙5┚2, ┙6┚2┚3 and ┙6┚2 are expressed on dopamine 
nerve terminals (Grady et al., 2007). Converging indication proposes that the dopaminergic 
system is important in mediating the pleasurable feelings of reward when activated by 
nicotine (Soderpalm et al., 2000; Zoli et al., 2002). It has been hypothesized that exposure to 
nicotine may initially increases the firing of ventral tegmental area GABAergic neurons 
through ┙7 nAChR activation, followed by 7 nAChR desensitization, that leads the 
disinhibition and firing of DA neurons. This latter event might be also enabled by a more 
prolonged activation of the ┙7 nAChR expressed on glutamatergic terminals (Wonnacott et 
al., 2005). At the molecular level, several studies have suggested that ERK1/2 activation 
followed by phosphorylation of Cyclic AMP Response Element Binding protein (CREB) at 
Ser133 and the activity of Fos gene are highly involved in many forms of experience 
dependent plasticity, such as long-term potentiation (LTP; Wu et al., 2007). FosB, a long-
lived truncated isoform of the FosB protein, accumulates within the striatum of rats treated 
repeatedly with either cocaine or nicotine, for several weeks and suggesting a sustained 
molecular change initiated by drug experience (Nestler, 2001), although not sufficient to 
account for the perseverance of drug dependence. CREB may play an important role in the 
rewarding and reinforcing effects of many drugs of abuse (Nestler, 2001, 2002), since pCREB 
is required in the NAc to establish nicotine-conditioned place preference (CPP) in mice 
(Brunzell et al., 2009).  
4. Genetic of nicotine addiction 
Meta-analysis of studies on twins showed that both genes and environment are important in 
smoking-related behaviours, with an estimated mean heritability of 0.50 for smoking 
initiation and 0.59 for nicotine dependence (Li et al., 2003). In women, genetic factors have a 
larger role in initiation than in persistence, whereas the opposite is observed in men (Li et 
al., 2003; Madden et al., 1999). Recent genome-wide association studies (GWAS) have shown 
that the CHRNA5-A3-B4 region, on chromosome 15q24-25.1, encoding the  and  
subunits, is strongly associated with nicotine dependence, as well as alcohol and cocaine 
dependence and lung cancer susceptibility (Amos et al., 2008; Amos et al., 2010; Bierut, 2010; 
Caporaso et al., 2009; Saccone et al., 2010; Spitz et al., 2008; Thorgeirsson et al., 2008). One of 
the strongest association within the 15q24-25.1 region is the rs16969968, located in exon 4 of 
CHRNA5, which causes an aminoacid substitution from an aspartic acid (D) to asparagine 
(N) (missense mutation) (D398N). This change reduces the ┙4┚2┙5 receptor function 
(Saccone et al. ,2007), as found by in vitro functional studies, which shown that  
receptors, containing the N substitution exhibited a weaker response to nicotine compared 
to the D variant in (Bierut et al., 2008). Other nAChR gene variants associated to ND are 
reported in Table 1. 
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Gene SNP 
Chromosome number/ 
position (base pairs) 
Major/Minor Allele 
CHRNA3 rs1051730 15/76681394 C/T 
CHRNA3 rs11637630 15/76686774 A/G 
CHRNA3 rs3743078 15/76681814 C/G 
CHRNA3 rs578776 15/76675455 C/T 
CHRNA3 rs7177514 15/76694461 C/G 
CHRNA3/B4 rs8023462 15/76701789 C/T 
CHRNA4 rs1044394 20/61452529 C/T 
CHRNA4 rs2236196 20/61448006 A/G 
CHRNA4 rs2273504 20/61458505 A/G 
CHRNA4 rs6122429 15/76701810 C/T 
CHRNA5 rs16969968 15/76669680 G/A 
CHRNA5 rs17486278 15/76654537 A/C 
CHRNA5 rs2036527 15/7663870 C/T 
CHRNA5 rs569207 15/76660174 GA 
CHRNA5 rs637137 15/7661031 T/A 
CHRNA5 rs8034191 15/45468658 G/A 
CHRNA6 rs1072003 8/42729008 C/G 
CHRNA6 rs2304297 8/42725148 C/G 
CHRNA6 rs892413 8/42727356 A/C 
CHRNB2 rs2072658 1/152806850 A/G 
CHRNB2 rs2072660 1/152815345 C/T 
CHRNB2 rs2072661 1/152815504 A/G 
CHRNB3 rs13280604 8/ 42678742 A/G 
CHRNB3 rs4950 8/42671789 C/T 
CHRNB4 rs1948 15/76704500 C/T 
Table 1. Association Results for Significant SNP–Phenotype Associations 'Current Frequent 
Smokers', Reviewed in Russo, 2011. 
5. Drugs in smoking cessation 
The drugs for smoking cessation currently approved by the FDA (Hurt et al., 2009) 
include nicotine-replacement therapy (NRT), Bupropion and Varenicline. A Cochrane 
Database of Systematic Reviews 2009 (Hajek et al., 2009) that reassessed different 
randomized or quasi-randomized controlled trials of relapse prevention interventions, 
with a minimum follow up of six months, concluded that: (i) extended treatment with 
Bupropion is unlikely to have a clinically important effect; (ii) studies of extended 
treatment with nicotine replacement are needed and (iii) extended treatment with 
Varenicline may prevent relapse.  
Varenicline [Systematic IUPAC name: 7,8,9,10-tetrahydro- 6,10-methano- 6H-pyrazino 
(2,3-h)(3) benzazepine (trade name Chantix), is an ┙4┚2 nicotinic receptor partial agonist 
and an 7 full agonist. The partial agonist activity induces modest receptor stimulation 
that attenuates the symptoms of nicotine withdrawal and inhibits the surges of dopamine 
release, responsible of the reinforcement and reward associated with smoking (Coe et al., 
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2005; Foulds, 2006). Consequently, Varenicline suppresses the symptoms of nicotine 
withdrawal and reduces the pharmacologic reward from cigarette smoking (Rollema et 
al., 2007).  
Bupropion [Systematic IUPAC name: (±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-
one], initially approved by the FDA as an atypical antidepressant, belongs to the chemical 
class of aminoketones. Although its mechanism of action in smoking cessation is not 
completely understood, Bupropion is an inhibitor of DA and of nor-epinephrine reuptake; 
but it is also a weak antagonist of nicotinic receptors (Cryan et al., 2003; Fryer & Lukas, 
1999;).  
6. Drugs and nAChR gene variants 
Although the association of nAChR variants and ND have been extensively studied, their 
role in drug therapy for smoking cessation is only pioneristic. Conti et al. (2008) have 
identified two polymorphisms within the CHRNB2 (rs2072661 and rs2072660) having 
significant association with the abstinence rates, within a 6-month follow-up study on the 
effects of Bupropion in smoking cessation, in a placebo-controlled trial. Specifically, 
although a difference was found in the relapse rates at EOT (end of treatment), between 
carriers and non-carriers, for individuals who received Bupropion, there was a substantial 
increase in the relapse rates for those individuals carrying the minor allele, after they went 
off treatment. Follow-up analyses on the top SNP (rs2072661) indicated a role in the time to 
relapse within the 6-month follow-up period and an impact on withdrawal symptoms at 
TQD (target quit date). These two SNPs (rs2072661 and rs2072660) may be robust markers 
for identifying smokers most likely to relapse and those who may benefit from Bupropion 
therapy. In addition, these SNPs should be examined within pharmacogenetic studies of 
Varenicline for smoking cessation. There is evidence that smokers with a heterozygous TC 
genotype at SNP rs2236196 in CHRNA4 are more likely to maintain abstinence with nicotine 
nasal spray (Hutchison et al., 2007). Moreover, looking at rs2072661, smokers with the 
CHRNB2 GG genotype, could sustain more days of abstinence during the nicotine versus 
placebo patch week, compared with those with the AG or AA genotypes; regardless of 
patch condition, quitting on the ‘target quit day’ was more likely to occur in those 
individuals with the GG genotype versus AA/AG genotypes. Genetic associations were not 
observed for craving or withdrawal responses to nicotine versus placebo patch (Perkins et 
al., 2009). A recent research studied the association of the CHRNA3 gene (Tyr215Tyr or 
rs1051730) with quitting success in response to controlled short-term nicotine patch use in 
hospitalized individuals (De Ruyck et al., 2010). Point abstinence was considered, and it was 
found that neither this genetic polymorphisms, nor the interaction of genotype versus 
treatment group, were significantly associated with quit rates, at any of the considered time 
points. A recent smoking cessation pharmacogenetics study (King et al., 2012) analyzed 1476 
consenting individuals (524 who take Varenicline; 440 Bupropion; 512 placebo). Among the 
subjects receiving Varenicline, two variants in CHRNB2 (rs3811450 and rs4262952) were 
significantly associated with continuous smoking abstinence. Interestingly Bupropion 
abstinence was associated with several SNPs within CYP2B6, one enzyme important for the 
metabolism of nicotine, including rs8109525. 
Indeed, CYP2B6.8 (the K139E variant) is unable to metabolize Bupropion under normal 
turnover conditions (Zhang et al., 2011). All these data support the evidence that genetic loci 
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contribute to smoking cessation and therapeutic response. On the other hand, the response 
treatment to Varenicline versus Bupropion is associated with different genetic signals, 
implying that in future research clinically useful markers shall guide treatment decisions to 
achieve improved smoking cessation rates and reduction in smoking occurrence.  
7. Conclusions 
Recognition that tobacco use is driven by the “neurobiological diseases” of “nicotine 
dependence” and “nicotine withdrawal”, linked to specific nAChR variants, provides a 
rational basis for the development of drugs and treatment, as well as supporting the 
inclusion of pharmacotherapies for dependence and withdrawal, along with those targeting 
other medical disorders. In fact, the need to prevent public health and economic 
devastation, caused by tobacco use, supports treatment as a high priority in health care. 
Pharmacotherapy for tobacco dependence is also cost effective when compared to many 
widely supported forms of pharmacotherapy for diseases, such as hypertension and 
hypercholesterolemia, as well as preventive periodic screening such as mammography or 
Papanicolaou smears. Moreover, the nAChR SNPs examination is less expensive and less 
invasive that spiral-CT or PET-SCAN examination, as screening in smokers. Taken together, 
these data suggest that genetic susceptibility to nicotine dependence is linked to several 
nAChR subtype genes and variants, in each subunit gene, and that may give independent, 
as well as interactive, contributions to nicotine dependency at molecular level. 
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